
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/504923/publications.pdf Version: 2024-02-01



Μιςμλει Ι Ηλιλάικλ

#	Article	IF	CITATIONS
1	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature, 2016, 537, 63-68.	27.8	521
2	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2018, 143, 37-50.	2.3	290
3	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. New England Journal of Medicine, 2015, 373, 1824-1834.	27.0	283
4	Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. Journal of Clinical Oncology, 2013, 31, 2532-2539.	1.6	261
5	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncology, The, 2018, 19, 337-346.	10.7	235
6	Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. Development (Cambridge), 2017, 144, 1775-1786.	2.5	228
7	Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. JAMA Oncology, 2015, 1, 814.	7.1	180
8	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
9	ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2015, 117, 559-581.	0.6	167
10	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2012, 119, S110-7.	2.3	149
11	Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecologic Oncology, 2005, 98, 274-280.	1.4	142
12	Cancer of the corpus uteri: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 45-60.	2.3	139
13	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
14	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematology,the, 2015, 2, e55-e65.	4.6	115
15	Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?. Gynecologic Oncology, 2013, 128, 6-11.	1.4	105
16	Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine, 2012, 10, 86.	5.5	103
17	Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. European Journal of Cancer, 2017, 83, 88-98.	2.8	93
18	Recurrent <i>PPP2R1A</i> Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. Cancer Research, 2016, 76, 5719-5731.	0.9	89

#	Article	IF	CITATIONS
19	Modeling Endometrial Cancer: Past, Present, and Future. International Journal of Molecular Sciences, 2018, 19, 2348.	4.1	82
20	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. Clinical Cancer Research, 2017, 23, 2223-2231.	7.0	80
21	Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study. Breast Journal, 2009, 15, 461-467.	1.0	79
22	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	21.4	77
23	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma. International Journal of Gynecological Cancer, 2014, 24, S67-S72.	2.5	75
24	Pregnancy and Cancer: the INCIP Project. Current Oncology Reports, 2020, 22, 17.	4.0	72
25	The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecologic Oncology, 2003, 90, 37-43.	1.4	71
26	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	7.0	71
27	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2015, 131, S96-104.	2.3	70
28	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	2.5	64
29	Management of cancer in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 741-753.	2.8	63
30	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
31	Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Modern Pathology, 2015, 28, 1001-1010.	5.5	60
32	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 2018, 142, 1230-1243.	5.1	59
33	Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecologic Oncology, 2004, 93, 680-685.	1.4	58
34	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncology, The, 2021, 22, 753-754.	10.7	57
35	ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecologic Oncology, 2004, 95, 583-587.	1.4	54
36	Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. European Journal of Cancer, 2014, 50, 1462-1471.	2.8	54

#	Article	IF	CITATIONS
37	Nuclear inclusion bodies of mutant and wildâ€ŧype p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. Journal of Pathology, 2017, 242, 24-38.	4.5	54
38	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecologic Oncology, 2015, 139, 118-126.	1.4	52
39	Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?. Brain Imaging and Behavior, 2018, 12, 64-77.	2.1	52
40	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
41	Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging. Gynecologic Oncology, 2015, 138, 299-303.	1.4	50
42	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
43	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 2019, 154, 531-538.	1.4	49
44	Effects of cancer treatment during pregnancy on fetal and child development. The Lancet Child and Adolescent Health, 2017, 1, 302-310.	5.6	48
45	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 2020, 63, 417-431.	1.6	48
46	Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. European Radiology, 2018, 28, 1862-1874.	4.5	46
47	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Modern Pathology, 2018, 31, 816-828.	5.5	46
48	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer, 2019, 19, 506.	2.6	46
49	Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecologic Oncology, 2006, 103, 1137-1140.	1.4	45
50	European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation. International Journal of Gynecological Cancer, 2017, 27, 189-192.	2.5	45
51	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2019, 6, e551-e561.	4.6	45
52	Strategies for fertility preservation in young early breast cancer patients. Breast, 2014, 23, 503-510.	2.2	42
53	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. EClinicalMedicine, 2021, 35, 100856.	7.1	42
54	Ovarian cancer in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 108-117.	2.8	41

#	Article	IF	CITATIONS
55	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188446.	7.4	41
56	Chemotherapy during pregnancy. Current Opinion in Oncology, 2012, 24, 580-586.	2.4	39
57	The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. Journal of Clinical Virology, 2014, 59, 18-23.	3.1	39
58	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 415-422.	1.4	38
59	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research, 2017, 23, 7232-7241.	7.0	37
60	Immunotherapy for cancer treatment during pregnancy. Lancet Oncology, The, 2021, 22, e550-e561.	10.7	37
61	Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Human Pathology, 2014, 45, 522-532.	2.0	36
62	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	3.3	35
63	Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. European Journal of Cancer, 2016, 65, 185-191.	2.8	35
64	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 2019, 154, 29-37.	1.4	35
65	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. International Journal of Gynecological Cancer, 2019, 29, 676-682.	2.5	35
66	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
67	Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecologic Oncology, 2003, 90, 372-377.	1.4	34
68	Potential Therapeutic Targets in Uterine Sarcomas. Sarcoma, 2015, 2015, 1-14.	1.3	34
69	Integration and validation of the ex vivo human placenta perfusion model. Journal of Pharmacological and Toxicological Methods, 2017, 88, 25-31.	0.7	34
70	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacology & Toxicology, 2015, 16, 2.	2.4	33
71	A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. Frontiers in Nutrition, 2018, 5, 138.	3.7	32
72	Psychological distress and cognitive coping in pregnant women diagnosed with cancer and their partners. Psycho-Oncology, 2017, 26, 1215-1221.	2.3	31

#	Article	IF	CITATIONS
73	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma <i>In Situ</i> . Cancer Research, 2019, 79, 1646-1657.	0.9	31
74	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	2.2	31
75	Staging for endometrial cancer: The controversy around lymphadenectomy – Can this be resolved?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 845-857.	2.8	30
76	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	7.0	30
77	The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. International Journal of Molecular Sciences, 2020, 21, 5409.	4.1	29
78	Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. Oncotarget, 2016, 7, 46120-46126.	1.8	29
79	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. Frontiers in Oncology, 2019, 9, 1073.	2.8	28
80	Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. European Journal of Cancer, 2016, 61, 52-60.	2.8	27
81	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. JAMA Network Open, 2021, 4, e2113180.	5.9	27
82	Gynecologic oncology in pregnancy. Critical Reviews in Oncology/Hematology, 2008, 67, 187-195.	4.4	26
83	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Gynecologic Oncology, 2015, 138, 165-173.	1.4	26
84	Imaging modalities in pregnant cancer patients. International Journal of Gynecological Cancer, 2021, 31, 423-431.	2.5	26
85	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	7.0	26
86	A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Research and Treatment, 2016, 156, 319-330.	2.5	25
87	Ageâ€dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. Human Brain Mapping, 2019, 40, 4994-5010.	3.6	25
88	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	8.4	25
89	Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature. Gynecologic Oncology, 2003, 88, 459-462.	1.4	24
90	Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. PLoS ONE, 2015, 10, e0124974.	2.5	23

#	Article	IF	CITATIONS
91	Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. Sarcoma, 2015, 2015, 1-14.	1.3	22
92	Morcellation of uterine leiomyomas: a plea for patient triage. Lancet Oncology, The, 2015, 16, 1454-1456.	10.7	22
93	Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. Case Reports in Oncology, 2018, 11, 119-124.	0.7	22
94	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	2.0	22
95	Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1811-1823.	2.5	21
96	The MNK1/2–elF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. Cancer Research, 2021, 81, 3876-3889.	0.9	21
97	Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article. International Journal of Gynecological Cancer, 2019, 29, 404-416.	2.5	21
98	A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 234-9.	2.8	21
99	Nonâ€invasive prenatal testing suggesting a maternal malignancy: What do we tell the prospective parents in Belgium?. Prenatal Diagnosis, 2021, 41, 1264-1272.	2.3	20
100	Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature. International Journal of Gynecological Cancer, 2009, 19, 245-248.	2.5	20
101	Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecologic Oncology, 2015, 138, 278-284.	1.4	19
102	Noninvasive Prenatal Testing and Detection of Occult Maternal Malignancies. Clinical Chemistry, 2019, 65, 1484-1486.	3.2	19
103	Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. British Journal of Radiology, 2016, 89, 20160468.	2.2	18
104	Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 79-88.	2.8	18
105	PARAGON (ANZGOC-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 2019, 30, e86.	2.2	18
106	Case report of a poorly differentiated uterine tumour with t(10;17) translocation and neuroectodermal phenotype. Anticancer Research, 2011, 31, 2367-71.	1.1	18
107	Maternal and obstetrical outcome in 35 cases of wellâ€differentiated thyroid carcinoma during pregnancy. Laryngoscope, 2018, 128, 1493-1500.	2.0	17
108	Pregnant women with confirmed neoplasms should not have noninvasive prenatal testing. Prenatal Diagnosis, 2019, 39, 1162-1165.	2.3	17

#	Article	IF	CITATIONS
109	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. Scientific Reports, 2021, 11, 3176.	3.3	17
110	Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 705384.	2.8	17
111	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. Gynecologic Oncology, 2017, 146, 538-545.	1.4	16
112	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. Journal of the Society for Gynecologic Investigation, 2003, 10, 105-109.	1.7	16
113	Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues?. BMC Cancer, 2018, 18, 192.	2.6	15
114	Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clinical Pharmacokinetics, 2021, 60, 775-784.	3.5	15
115	Maternal and neonatal outcomes in 80 patients diagnosed with nonâ€Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. British Journal of Haematology, 2021, 193, 52-62.	2.5	14
116	Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. International Journal of Gynecological Cancer, 2021, 31, 412-422.	2.5	14
117	Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. Cancers, 2021, 13, 3988.	3.7	14
118	Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions. Cancers, 2022, 14, 1966.	3.7	14
119	Cumulative dosage effect of aRAD51l1/HMGA2 fusion and RAD51l1 loss in a case of pseudo-Meigs' syndrome. Genes Chromosomes and Cancer, 2001, 32, 324-329.	2.8	12
120	2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. Gynecologic Oncology, 2003, 91, 299-308.	1.4	12
121	A possible role of the cytochrome P450c17α gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 234-239.	2.8	12
122	Development of Patient-Derived Tumor Xenograft Models. Methods in Molecular Biology, 2019, 1862, 217-225.	0.9	12
123	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
124	Contraception is as important as fertility preservation in young women with cancer. Lancet, The, 2015, 385, 508.	13.7	11
125	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. Endoscopy, 2016, 48, 1016-1022.	1.8	10
126	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	6.4	10

#	Article	IF	CITATIONS
127	Laparoscopic Power Morcellation: Techniques to Avoid Tumoral Spread. Journal of Minimally Invasive Gynecology, 2021, 28, 1442-1443.	0.6	10
128	Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer. Gynecologic Oncology, 2020, 159, 335-343.	1.4	10
129	Incorporating molecular profiling into endometrial cancer management requires prospective studies. International Journal of Gynecological Cancer, 2021, 31, 944-945.	2.5	10
130	Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer. Gynecologic Oncology, 2021, 162, 360-367.	1.4	10
131	The "Leuven―paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. Gynecologic Oncology, 2013, 128, 34-37.	1.4	9
132	Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. Lancet Oncology, The, 2016, 17, 273-274.	10.7	9
133	Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 61-67.	2.5	9
134	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. Acta Clinica Belgica, 2020, 75, 9-18.	1.2	9
135	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. Frontiers in Oncology, 2020, 10, 538064.	2.8	9
136	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. Clinical Chemistry, 2020, 66, 1414-1423.	3.2	9
137	Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2021, 222, 113562.	5.5	9
138	TRP channel expression correlates with the epithelial–mesenchymal transition and high-risk endometrial carcinoma. Cellular and Molecular Life Sciences, 2022, 79, 1.	5.4	9
139	High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. Journal of Medical Case Reports, 2010, 4, 243.	0.8	8
140	Prospective Randomized Study of <scp>MiniArc</scp> and Ajust Single Incision Sling Procedures. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 172-174.	1.3	8
141	Characteristics and prognosis of patients with early-stage endometrial cancer who refuse adjuvant radiotherapy. Gynecologic Oncology, 2016, 141, 428-433.	1.4	8
142	Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Oncological outcomes. Gynecologic Oncology, 2021, 163, 100-104.	1.4	8
143	The misoprostal third stage study: a randomsed controlled comparison between orally administreted misoprostol and standard management A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 338-338.	2.3	7
144	Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLoS ONE, 2017, 12, e0182223.	2.5	7

#	Article	IF	CITATIONS
145	Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. Vaccines, 2018, 6, 56.	4.4	7
146	Executive functioning in 6Âyear old children exposed to chemotherapy in utero. Early Human Development, 2020, 151, 105198.	1.8	7
147	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	2.8	7
148	Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. European Journal of Surgical Oncology, 2022, 48, 896-902.	1.0	7
149	Effects of prenatal exposure to cancer treatment on neurocognitive development, a review. NeuroToxicology, 2016, 54, 11-21.	3.0	6
150	Placental pathology in cancer during pregnancy and after cancer treatment exposure. Placenta, 2021, 111, 33-46.	1.5	6
151	2â€ ² -deoxy-2â€ ² -[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. Oncotarget, 2018, 9, 28572-28585.	1.8	6
152	Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. Anticancer Research, 2016, 36, 5381-5384.	1.1	6
153	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clinical Chemistry, 2022, 68, 1164-1176.	3.2	6
154	The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. Gynecologic Oncology, 2015, 138, 378-382.	1.4	5
155	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1	1 0,78431 0.9	4 rgBT /Overl
156	Comment on "Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review― European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 216, 261-262.	1.1	5
157	Squamous cell carcinoma with sarcomatoid differentiation or carcinosarcoma of the uterine cervix associated with HPV33 infection: report of a rare case. Diagnostic Pathology, 2020, 15, 12.	2.0	5
158	External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. Gynecologic Oncology, 2016, 142, 83-88.	1.4	4
159	Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey. International Journal of Gynecological Cancer, 2019, 29, 1425-1430.	2.5	4
160	Morcellation of the Uterus: Is There Any Place?. Current Oncology Reports, 2020, 22, 68.	4.0	4
161	Renal and Bladder Cancer During Pregnancy: A Review of 47 Cases and Literature-based Recommendations for Management. Urology, 2021, 151, 118-128.	1.0	4
162	Cervical cancer in pregnancy at various gestational ages. International Journal of Gynecological Cancer, 2021, 31, 784-788.	2.5	4

#	Article	IF	CITATIONS
163	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers, 2021, 13, 2040.	3.7	4
164	Fertility sparing treatment in cervical cancer management in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 75, 101-112.	2.8	4
165	Extracorporeal shock wave therapy for treatment of vulvodynia: a prospective, randomized, double-blind, placebo-controlled study. European Journal of Physical and Rehabilitation Medicine, 2020, 56, 169-174.	2.2	4
166	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. International Journal of Molecular Sciences, 2016, 17, 1525.	4.1	3
167	Long-term impact of prenatal exposure to chemotherapy on executive functioning: An ERP study. Clinical Neurophysiology, 2019, 130, 1655-1664.	1.5	3
168	Extracorporeal shock wave therapy for treating dyspareunia: A prospective, randomized, double-blind, placebo-controlled study. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101545.	2.3	3
169	Fertility-sparing surgery after neo-adjuvant chemotherapy in women with cervical cancer larger than 4 cm: a systematic review. International Journal of Gynecological Cancer, 2022, 32, 486-493.	2.5	3
170	Chemotherapy for cervical cancer. European Clinics in Obstetrics and Gynaecology, 2005, 1, 143-150.	0.4	2
171	Reply to H.A. Azim Jr et al. Journal of Clinical Oncology, 2010, 28, e304-e304.	1.6	2
172	Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed childrenÂwith nonexposed controls. American Journal of Obstetrics and Gynecology, 2015, 212, 830-831.	1.3	2
173	Treatment of gynecological cancers diagnosed during pregnancy. Future Oncology, 2016, 12, 2265-2275.	2.4	2
174	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	1.0	2
175	Implementation of cancer treatment during pregnancy in daily practice: the important role of perinatologists. Oncotarget, 2018, 9, 31795-31796.	1.8	2
176	Atypical Lesions of the Breast and Lobular Carcinoma in Situ in Pregnancy – Surgeons' Practice. The Journal of Breast Health, 2020, 16, 16-21.	1.0	1
177	Analysis of awareness and acceptance of SARS-CoV-2 vaccination among pregnant women. Ceska Gynekologie, 2022, 87, 100-103.	0.3	1
178	Different Subtypes of Uterine Sarcoma Require a Separate Therapeutic Approach. Women's Health, 2005, 1, 375-383.	1.5	0
179	Revised FIGO staging for endometrial cancer. Southern African Journal of Gynaecological Oncology, 2010, 2, 40-41.	0.3	0
180	Low-grade bronchial mucoepidermoid carcinoma during pregnancy successfully treated by lobectomy. Journal of Obstetrics and Gynaecology, 2017, 37, 1082-1084.	0.9	0

#	Article	IF	CITATIONS
181	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. Reproductive Sciences, 2018, 25, 1637-1648.	2.5	0
182	AUTHOR REPLY. Urology, 2021, 151, 127-128.	1.0	0